WO2010019148A1 - Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography - Google Patents

Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography Download PDF

Info

Publication number
WO2010019148A1
WO2010019148A1 PCT/US2008/073179 US2008073179W WO2010019148A1 WO 2010019148 A1 WO2010019148 A1 WO 2010019148A1 US 2008073179 W US2008073179 W US 2008073179W WO 2010019148 A1 WO2010019148 A1 WO 2010019148A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
membrane
antibody
antibodies
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/073179
Other languages
English (en)
French (fr)
Inventor
Arick Brown
Jerome Bill, Jr.
Timothy Tully
Christopher Dowd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39899038&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010019148(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK14189582.1T priority Critical patent/DK2848625T3/da
Priority to EP14189582.1A priority patent/EP2848625B1/en
Priority to LTEP14189582.1T priority patent/LT2848625T/lt
Priority to SI200832219T priority patent/SI3604324T1/sl
Priority to ES08797895T priority patent/ES2527943T5/es
Priority to LTEP19181531.5T priority patent/LT3604324T/lt
Priority to KR1020187036563A priority patent/KR102196883B1/ko
Priority to HRP20240472TT priority patent/HRP20240472T1/hr
Priority to PT191815315T priority patent/PT3604324T/pt
Priority to CA2731943A priority patent/CA2731943C/en
Priority to RSP20191119 priority patent/RS59232B1/sr
Priority to ES19181531T priority patent/ES2978373T3/es
Priority to PT141895821T priority patent/PT2848625T/pt
Priority to CN200880131059.7A priority patent/CN102149724B/zh
Priority to SI200832092T priority patent/SI2848625T1/sl
Priority to EP08797895.3A priority patent/EP2321337B2/en
Priority to DK19181531.5T priority patent/DK3604324T3/da
Priority to ES14189582T priority patent/ES2749190T3/es
Priority to EP19181531.5A priority patent/EP3604324B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to HUE19181531A priority patent/HUE066562T2/hu
Priority to JP2011522953A priority patent/JP5666447B2/ja
Priority to KR1020187008461A priority patent/KR20180033311A/ko
Priority to AU2008360625A priority patent/AU2008360625C1/en
Priority to US13/058,796 priority patent/US10927144B2/en
Priority to PL19181531.5T priority patent/PL3604324T3/pl
Priority to KR1020117005824A priority patent/KR101843915B1/ko
Priority to PCT/US2008/073179 priority patent/WO2010019148A1/en
Priority to PL14189582T priority patent/PL2848625T3/pl
Priority to FIEP19181531.5T priority patent/FI3604324T3/fi
Priority to HUE14189582A priority patent/HUE047316T2/hu
Priority to BRPI0823046-3A priority patent/BRPI0823046B1/pt
Priority to MX2011001506A priority patent/MX2011001506A/es
Publication of WO2010019148A1 publication Critical patent/WO2010019148A1/en
Priority to IL210912A priority patent/IL210912B/en
Anticipated expiration legal-status Critical
Priority to HK15109226.0A priority patent/HK1210181B/en
Priority to IL262657A priority patent/IL262657B/en
Priority to CY20191101072T priority patent/CY1122221T1/el
Priority to HRP20191848TT priority patent/HRP20191848T1/hr
Priority to US17/153,826 priority patent/US20210284685A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Definitions

  • contaminant is a material that is different from the desired polypeptide product.
  • the contaminant includes, without limitation: host cell materials, such as Chinese Hamster Ovary Proteins (CHOP); leached protein ⁇ ; nucleic acid; a variant, fragment, aggregate, isomer or derivative of the desired polypeptide; another polypeptide; endotoxin; viral contaminant; cell culture media component (e.g., garamycin; GENT ⁇ MYCIN ⁇ ) etc.
  • host cell materials such as Chinese Hamster Ovary Proteins (CHOP); leached protein ⁇ ; nucleic acid; a variant, fragment, aggregate, isomer or derivative of the desired polypeptide; another polypeptide; endotoxin; viral contaminant; cell culture media component (e.g., garamycin; GENT ⁇ MYCIN ⁇ ) etc.
  • Multispecific antibodies have binding specificities for at least two different epitopes, where the epitopes are usually from different antigens. While such molecules normally will only bind two antigens ⁇ i.e., bispecific antibodies, BsAbs), antibodies with additional specificities such as trispecific antibodies are encompassed by this expression when used herein.
  • trispecific antibodies examples include anti-CD3/anti-CD4/anti-CD37, anti-CD3/anti- CD5/anti-CD37 and anti-CD3/anti-CD8/anti-CD37.
  • Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., F(ab') 2 bispecific antibodies).
  • E. coli cloning host is E. coli 294 (ATCC 31,446), although other strains such as E. coli B, E. coli Xl 776 (ATCC 31,537), and E. coli W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting.
  • cukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody encoding vectors.
  • vertebrate cells have been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure.
  • useful mammalian host cell lines include, but arc not limited to, monkey kidney CVl cells transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney cells (293 or 293 cells subcloned for growth in suspension culture, Graham et ⁇ l., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary ccllsADHFR (CHO, Urlaub el ⁇ l., Proc. N ⁇ tl. Ac ⁇ d.
  • COS-7 monkey kidney CVl cells transformed by SV40
  • human embryonic kidney cells (293 or 293 cells subcloned for growth in suspension culture, Graham et ⁇ l., J. Gen Virol. 36:59 (1977)
  • baby hamster kidney cells BHK, ATCC CCL 10
  • any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as garamycin; GENTAMYCIN®), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
  • the culture conditions such as temperature, pi I, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • the composition to be subjected to the purification method herein is a recombinantly produced antibody, preferably an intact antibody, expressed by a Chinese Hamster Ovary (CIIO) recombinant host cell culture.
  • the composition has been subjected to at least one purification step prior to membrane ion exchange chromatography.
  • the composition contains the antibody of interest and one or more contaminants, such as Chinese Hamster Ovary Proteins (CHOP); leached protein ⁇ ; nucleic acid; a variant, fragment, aggregate or derivative of the desired antibody; another polypeptide; endotoxin; viral contaminant; cell culture media component (e g., garamycin; GHNTAMYCIN®), etc.
  • membrane chromatography is run on either a standard chromatography system or a custom chromatography system like an AKTATM Explorer (GE Healthcare) equipped with pressure gauges, sensors, and pump plus pump controllers.
  • the membrane device is installed downstream of a pressure gauge.
  • the pll and conductivity detectors are installed downstream of the membrane device.
  • the system is thoroughly flushed with water and then with equilibration buffer before the installation of the membrane.
  • the system with the membrane is flushed with equilibration buffer until the solution pll and conductivity outlet match the equilibration buffer specification (about five membrane volumes) and a stable baseline is observed.
  • the antibody purified as disclosed herein or the composition comprising the antibody and a pharmaceutically acceptable carrier is then used for various diagnostic, therapeutic or other uses known for such antibodies and compositions.
  • the antibody may be used to treat a disorder in a mammal by administering a therapeutically effective amount of the antibody to the mammal.
  • Fairfield, Connecticut which is a programmable process purification system that includes an integrated metering pump, pressure sensor, and in-line pH, conductivity, and UV sensor.
  • the Explorer system was programmed and controlled through a computer running UNICORNTM v5.10 software (GE Healthcare, Fairfield, Connecticut). Small- scale tests were also performed using a manual system consisting of a Masterflex® L/S® digital economy drive peristaltic pump (Cole Parmer, Vernon Hills, Illinois), in-line DTXTM Plus 1 ' NF-R pressure sensor (Becton Dickinson, Franklin Lakes, New Jersey), and a AND EK- 120Oi balance ( ⁇ &D Company, Ltd., Tokyo, Japan). The balance was used to physically monitor the flow rate of the pump by measuring mass accumulation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/US2008/073179 2008-08-14 2008-08-14 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography Ceased WO2010019148A1 (en)

Priority Applications (38)

Application Number Priority Date Filing Date Title
MX2011001506A MX2011001506A (es) 2008-08-14 2008-08-14 Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena.
HUE19181531A HUE066562T2 (hu) 2008-08-14 2008-08-14 Eljárások szennyezés eltávolítására indigén fehérje kiszorításos ioncserés membrán kromatográfia alkalmazásával
KR1020187008461A KR20180033311A (ko) 2008-08-14 2008-08-14 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법
SI200832219T SI3604324T1 (sl) 2008-08-14 2008-08-14 Postopki za odstranjevanje kontaminata z uporabo ionskoizmenjevalne membranske kromatografije z izpodrinjenjem nativnega proteina
ES08797895T ES2527943T5 (es) 2008-08-14 2008-08-14 Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas
LTEP19181531.5T LT3604324T (lt) 2008-08-14 2008-08-14 Metodai, skirti priemaišų pašalinimui panaudojant jonų mainų chromatografiją su vietiniu išstūmimu
KR1020187036563A KR102196883B1 (ko) 2008-08-14 2008-08-14 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법
HRP20240472TT HRP20240472T1 (hr) 2008-08-14 2008-08-14 Postupci za eliminaciju kontaminanta uporabom kromatografije membranske ionske izmjene s premještanjem urođenog proteina
PT191815315T PT3604324T (pt) 2008-08-14 2008-08-14 Métodos para remover um contaminante com a utilização de cromatografia de membrana de permuta iónica de deslocação de proteína indígena
CA2731943A CA2731943C (en) 2008-08-14 2008-08-14 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
RSP20191119 RS59232B1 (sr) 2008-08-14 2008-08-14 Postupci za uklanjanje zagađivača koristeći hromatografiju membrane razmene jona sa razmeštanjem autohtonih proteina
ES19181531T ES2978373T3 (es) 2008-08-14 2008-08-14 Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
PT141895821T PT2848625T (pt) 2008-08-14 2008-08-14 Métodos para remover um contaminante com a utilização de cromatografia de membrana de permuta iónica de deslocação de proteína indígena.
CN200880131059.7A CN102149724B (zh) 2008-08-14 2008-08-14 使用原地蛋白质置换离子交换膜层析清除污染物的方法
SI200832092T SI2848625T1 (sl) 2008-08-14 2008-08-14 Postopki za odstranjevanje kontaminanta z uporabo ionskoizmenjevalne membranske kromatografije z izpodrinjenjem nativnega proteina
EP08797895.3A EP2321337B2 (en) 2008-08-14 2008-08-14 Methods for removing a contaminant using protein displacement ion exchange membrane chromatography
DK19181531.5T DK3604324T3 (da) 2008-08-14 2008-08-14 Fremgangsmåder til at fjerne en kontaminant under anvendelse af ionbytningskromatografi med forskydning af iboende proteiner
ES14189582T ES2749190T3 (es) 2008-08-14 2008-08-14 Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
EP19181531.5A EP3604324B1 (en) 2008-08-14 2008-08-14 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
DK14189582.1T DK2848625T3 (da) 2008-08-14 2008-08-14 Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
JP2011522953A JP5666447B2 (ja) 2008-08-14 2008-08-14 常在性タンパク質置換イオン交換メンブレンクロマトグラフィを用いた混入物除去方法
EP14189582.1A EP2848625B1 (en) 2008-08-14 2008-08-14 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
LTEP14189582.1T LT2848625T (lt) 2008-08-14 2008-08-14 Priemaišų pašalinimo būdai, panaudojant reziduojančio baltymo pakeitimą jonų mainų membraninės chromatografijos pagalba
AU2008360625A AU2008360625C1 (en) 2008-08-14 2008-08-14 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
US13/058,796 US10927144B2 (en) 2008-08-14 2008-08-14 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
PL19181531.5T PL3604324T3 (pl) 2008-08-14 2008-08-14 Sposoby usuwania zanieczyszczeń za pomocą chromatografii membranowej jonowymiennej z zastąpieniem macierzystego białka
KR1020117005824A KR101843915B1 (ko) 2008-08-14 2008-08-14 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법
PCT/US2008/073179 WO2010019148A1 (en) 2008-08-14 2008-08-14 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
PL14189582T PL2848625T3 (pl) 2008-08-14 2008-08-14 Sposoby usuwania zanieczyszczeń za pomocą chromatografii membranowej jonowymiennej z zastąpieniem macierzystego białka
FIEP19181531.5T FI3604324T3 (fi) 2008-08-14 2008-08-14 Menetelmiä epäpuhtauden poistamiseksi käyttäen luontaisen proteiinin syrjäytyksen ioninvaihtomembraanikromatografiaa
HUE14189582A HUE047316T2 (hu) 2008-08-14 2008-08-14 Eljárások szennyezés eltávolítására indigén fehérjekiszorításos ioncserés membrán kromatográfia alkalmazásával
BRPI0823046-3A BRPI0823046B1 (pt) 2008-08-14 2008-08-14 Método para purificar um anticorpo monoclonal de uma composição compreendendo o anticorpo monoclonal e pelo menos uma proteína de ovário de hamster chinês (chop)
IL210912A IL210912B (en) 2008-08-14 2011-01-27 Methods for removing a contaminant using natural protein transfer in ion exchange membrane chromatography
HK15109226.0A HK1210181B (en) 2015-09-18 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
IL262657A IL262657B (en) 2008-08-14 2018-10-28 Methods for removing a contaminant using natural protein transfer in ion exchange membrane chromatography
CY20191101072T CY1122221T1 (el) 2008-08-14 2019-10-11 Μεθοδοι αφαιρεσης ρυπου χρησιμοποιωντας ιοντοανταλλακτικη μεμβρανικη χρωματογραφια μετατοπισης γηγενων πρωτεϊνων
HRP20191848TT HRP20191848T1 (hr) 2008-08-14 2019-10-14 Postupci odstranjivanja kontaminanta uporabom membranske kromatografije ionskom izmjenom s premještanjem autohtonog proteina
US17/153,826 US20210284685A1 (en) 2008-08-14 2021-01-20 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/073179 WO2010019148A1 (en) 2008-08-14 2008-08-14 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/058,796 A-371-Of-International US10927144B2 (en) 2008-08-14 2008-08-14 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
US17/153,826 Continuation US20210284685A1 (en) 2008-08-14 2021-01-20 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography

Publications (1)

Publication Number Publication Date
WO2010019148A1 true WO2010019148A1 (en) 2010-02-18

Family

ID=39899038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/073179 Ceased WO2010019148A1 (en) 2008-08-14 2008-08-14 Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography

Country Status (22)

Country Link
US (2) US10927144B2 (https=)
EP (3) EP2321337B2 (https=)
JP (1) JP5666447B2 (https=)
KR (3) KR20180033311A (https=)
CN (1) CN102149724B (https=)
AU (1) AU2008360625C1 (https=)
BR (1) BRPI0823046B1 (https=)
CA (1) CA2731943C (https=)
CY (1) CY1122221T1 (https=)
DK (2) DK3604324T3 (https=)
ES (3) ES2527943T5 (https=)
FI (1) FI3604324T3 (https=)
HR (2) HRP20240472T1 (https=)
HU (2) HUE047316T2 (https=)
IL (2) IL210912B (https=)
LT (2) LT3604324T (https=)
MX (1) MX2011001506A (https=)
PL (2) PL3604324T3 (https=)
PT (2) PT3604324T (https=)
RS (1) RS59232B1 (https=)
SI (2) SI2848625T1 (https=)
WO (1) WO2010019148A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012030512A1 (en) * 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2013096322A1 (en) * 2011-12-22 2013-06-27 Genentech, Inc Ion exchange membrane chromatography
EP2649088A4 (en) * 2010-12-10 2014-09-03 Tracy Thompson COMPOSITIONS FOR SEPARATION METHODS
WO2019246153A1 (en) * 2018-06-19 2019-12-26 Bristol-Myers Squibb Company Methods of purifying proteins using chromatography
CN110944942A (zh) * 2017-09-07 2020-03-31 雪佛龙美国公司 Afx骨架类型分子筛的合成
EP2575847B2 (en) † 2010-05-25 2022-04-27 F. Hoffmann-La Roche AG Methods of purifying polypeptides
US20220275024A1 (en) * 2019-08-15 2022-09-01 Fujifilm Diosynth Biotechnologies Uk Limited Process for Purifying Monoclocal Antibodies

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
BRPI0823046B1 (pt) 2008-08-14 2021-12-14 Genentech, Inc Método para purificar um anticorpo monoclonal de uma composição compreendendo o anticorpo monoclonal e pelo menos uma proteína de ovário de hamster chinês (chop)
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
BRPI0920572A8 (pt) 2008-10-20 2015-10-27 Abbott Lab Inativação viral durante a purificação dos anticorpos
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014133458A1 (en) * 2013-02-26 2014-09-04 Agency For Science, Technology And Research Protein purification in the presence of nonionic organic polymers and electropositive surfaces
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
JP6163541B2 (ja) * 2013-04-16 2017-07-12 旭化成メディカル株式会社 抗体タンパク質の精製方法
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US9546208B2 (en) 2014-01-03 2017-01-17 Bio-Rad Laboratories, Inc. Removal of impurities from protein A eluates
RU2759909C2 (ru) * 2016-09-07 2021-11-18 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы очистки антител
CN109689189B (zh) 2016-09-09 2022-02-01 3M创新有限公司 官能化共聚物及其使用
EP3546475A1 (en) * 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
TWI903214B (zh) * 2018-05-02 2025-11-01 美商里珍納龍藥品有限公司 用於評估生化過濾器的適合性的方法
CN109324143B (zh) * 2018-10-19 2021-10-29 张骐 利用二维液相分离制备抗体类产品相关杂质的方法
CN109806916B (zh) * 2019-03-15 2021-12-21 中科森辉微球技术（苏州）有限公司 高性能阴离子交换介质及其制备方法
KR20220112014A (ko) 2021-02-03 2022-08-10 고인석 십전대보탕을 이용하여 만든 오리목뼈 간식
EP4423109A4 (en) * 2021-10-27 2025-12-24 Plasma Tech Llc COMPOSITIONS AND METHODS FOR ISOLATING PROTEINS
WO2025221920A1 (en) * 2024-04-18 2025-10-23 Makana Therapeutics, Inc. Products and methods relating to transplant recipient antibodies bound to donor cell membrane fragments
CN118290514B (zh) * 2024-06-05 2025-04-04 东曜药业有限公司 基于阴离子膜的抗体偶联药物的纯化方法及抗体偶联药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068452A2 (en) * 2001-02-22 2002-09-06 Plant Bioscience Limited Method of isolating charged compounds, especially peptides and proteins
US20020187206A1 (en) * 2000-04-11 2002-12-12 Mirkov T. Erik Method and apparatus for fractional separation of proteins from plant material

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4347322A (en) 1981-01-12 1982-08-31 Nabisco Brands, Inc. Chromatographic process for enzyme purification
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2193136T3 (es) 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CA2106612C (en) † 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
ES2108566T3 (es) 1993-12-10 1997-12-16 Genentech Inc Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
WO1995019181A1 (en) 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US6592905B1 (en) 1996-01-31 2003-07-15 Massey University Production of an immunoglobulin enriched fraction from whey protein solutions
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0941344B1 (en) 1996-11-27 2004-05-19 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
NZ507557A (en) * 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2309012T3 (es) 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
US6633462B2 (en) 2000-07-13 2003-10-14 Koninklijke Philips Electronics N.V. Magnetoresistive angle sensor having several sensing elements
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
AU2002351495A1 (en) 2001-10-17 2003-04-28 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003068821A2 (en) 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
WO2003102132A2 (en) † 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
EP3225625A1 (en) * 2002-09-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Protein purification method
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
CN1802388B (zh) 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR101221862B1 (ko) † 2003-10-27 2013-01-14 와이어쓰 엘엘씨 하이드록시아파타이트 크로마토그래피를 사용한 고분자량응집체의 제거
CN101155831B (zh) 2005-02-10 2015-08-19 贝勒研究院 抗干扰素α单克隆抗体及其使用方法
EP1869065B1 (en) † 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
CA2645739A1 (en) * 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
EP2054521A4 (en) * 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
WO2009135656A1 (en) 2008-05-06 2009-11-12 Lonza Biologics Plc. A method for the purification of antibodies using displacement chromatography
BRPI0823046B1 (pt) 2008-08-14 2021-12-14 Genentech, Inc Método para purificar um anticorpo monoclonal de uma composição compreendendo o anticorpo monoclonal e pelo menos uma proteína de ovário de hamster chinês (chop)
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187206A1 (en) * 2000-04-11 2002-12-12 Mirkov T. Erik Method and apparatus for fractional separation of proteins from plant material
WO2002068452A2 (en) * 2001-02-22 2002-09-06 Plant Bioscience Limited Method of isolating charged compounds, especially peptides and proteins

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12152054B2 (en) 2010-05-25 2024-11-26 Genentech, Inc. Methods of purifying polypeptides
EP3299380B1 (en) 2010-05-25 2024-08-28 F. Hoffmann-La Roche AG Methods of purifying polypeptides
EP2575847B2 (en) † 2010-05-25 2022-04-27 F. Hoffmann-La Roche AG Methods of purifying polypeptides
WO2012030512A1 (en) * 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
EP2649088A4 (en) * 2010-12-10 2014-09-03 Tracy Thompson COMPOSITIONS FOR SEPARATION METHODS
KR102067075B1 (ko) 2011-12-22 2020-01-17 제넨테크, 인크. 이온 교환 막 크로마토그래피
IL267585B (en) * 2011-12-22 2022-09-01 Genentech Inc Ion exchange membrane chromatography
RU2648999C2 (ru) * 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
CN104125963B (zh) * 2011-12-22 2018-08-17 弗·哈夫曼-拉罗切有限公司 使用离子交换膜层析改进下游蛋白质纯化步骤的方法
US10364268B2 (en) 2011-12-22 2019-07-30 Genentech, Inc. Ion exchange membrane chromatography
AU2018200194B2 (en) * 2011-12-22 2019-11-14 Genentech, Inc. Ion exchange membrane chromatography
WO2013096322A1 (en) * 2011-12-22 2013-06-27 Genentech, Inc Ion exchange membrane chromatography
JP2015503524A (ja) * 2011-12-22 2015-02-02 ジェネンテック， インコーポレイテッド イオン交換膜クロマトグラフィー
JP2020040952A (ja) * 2011-12-22 2020-03-19 ジェネンテック， インコーポレイテッド イオン交換膜クロマトグラフィー
KR20140114834A (ko) * 2011-12-22 2014-09-29 제넨테크, 인크. 이온 교환 막 크로마토그래피
JP2021169454A (ja) * 2011-12-22 2021-10-28 ジェネンテック， インコーポレイテッド イオン交換膜クロマトグラフィー
CN104125963A (zh) * 2011-12-22 2014-10-29 弗·哈夫曼-拉罗切有限公司 使用离子交换膜层析改进下游蛋白质纯化步骤的方法
US11945837B2 (en) 2011-12-22 2024-04-02 Genentech, Inc. Ion exchange membrane chromatography
AU2012355356B2 (en) * 2011-12-22 2017-10-12 Genentech, Inc. Ion exchange membrane chromatography
JP7359807B2 (ja) 2011-12-22 2023-10-11 ジェネンテック， インコーポレイテッド イオン交換膜クロマトグラフィー
CN110944942B (zh) * 2017-09-07 2023-01-24 雪佛龙美国公司 Afx骨架类型分子筛的合成
CN110944942A (zh) * 2017-09-07 2020-03-31 雪佛龙美国公司 Afx骨架类型分子筛的合成
WO2019246153A1 (en) * 2018-06-19 2019-12-26 Bristol-Myers Squibb Company Methods of purifying proteins using chromatography
US20220275024A1 (en) * 2019-08-15 2022-09-01 Fujifilm Diosynth Biotechnologies Uk Limited Process for Purifying Monoclocal Antibodies
US12559519B2 (en) * 2019-08-15 2026-02-24 Fujifilm Diosynth Biotechnologies Uk Limited Process for purifying monoclocal antibodies

Also Published As

Publication number Publication date
EP2321337B1 (en) 2014-10-22
PT3604324T (pt) 2024-05-10
LT3604324T (lt) 2024-05-10
DK3604324T3 (da) 2024-04-08
IL262657A (en) 2018-12-31
HRP20240472T1 (hr) 2024-06-21
DK2848625T3 (da) 2019-10-07
AU2008360625B2 (en) 2016-05-19
KR102196883B1 (ko) 2020-12-30
SI2848625T1 (sl) 2019-11-29
ES2978373T3 (es) 2024-09-11
BRPI0823046A2 (pt) 2015-07-28
PL2848625T3 (pl) 2020-01-31
EP2321337B2 (en) 2018-10-10
LT2848625T (lt) 2019-10-10
CN102149724A (zh) 2011-08-10
US20120122759A1 (en) 2012-05-17
HRP20191848T1 (hr) 2019-12-27
KR20180033311A (ko) 2018-04-02
US20210284685A1 (en) 2021-09-16
CN102149724B (zh) 2014-04-09
EP2321337B9 (en) 2016-11-30
SI3604324T1 (sl) 2024-06-28
EP2321337A1 (en) 2011-05-18
FI3604324T3 (fi) 2024-05-16
CA2731943A1 (en) 2010-02-18
CY1122221T1 (el) 2020-11-25
EP2848625A1 (en) 2015-03-18
BRPI0823046B1 (pt) 2021-12-14
AU2008360625C1 (en) 2017-01-19
IL210912A0 (en) 2011-04-28
KR20110067099A (ko) 2011-06-21
EP3604324A1 (en) 2020-02-05
RS59232B1 (sr) 2019-10-31
JP2011530592A (ja) 2011-12-22
ES2527943T5 (es) 2019-03-07
MX2011001506A (es) 2011-03-15
AU2008360625A1 (en) 2010-02-18
HK1210181A1 (en) 2016-04-15
PT2848625T (pt) 2019-10-25
JP5666447B2 (ja) 2015-02-12
HUE047316T2 (hu) 2020-04-28
EP3604324B1 (en) 2024-02-28
IL210912B (en) 2019-03-31
CA2731943C (en) 2016-11-29
IL262657B (en) 2021-03-25
KR20180137591A (ko) 2018-12-27
ES2749190T3 (es) 2020-03-19
US10927144B2 (en) 2021-02-23
ES2527943T3 (es) 2015-02-02
HUE066562T2 (hu) 2024-08-28
KR101843915B1 (ko) 2018-04-02
PL3604324T3 (pl) 2024-07-01
EP2848625B1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
US20210284685A1 (en) Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
US20240247027A1 (en) Ion exchange membrane chromatography
HK1210181B (en) Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
NZ626949B2 (en) Ion exchange membrane chromatography
HK1203526B (zh) 使用离子交换膜层析改进下游蛋白质纯化步骤的方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880131059.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08797895

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2731943

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008360625

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 623/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/001506

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2011522953

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008360625

Country of ref document: AU

Date of ref document: 20080814

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008797895

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117005824

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13058796

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0823046

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110211